St. Jude Medical launches new cardiac rhythm management devices

St. Jude Medical, Inc. (NYSE:STJ) today announced it has launched several new cardiac rhythm management devices for the treatment and diagnosis of abnormal heart rhythms. The company announced Australian Therapeutic Goods Administration (TGA) approval of the Current™ Accel implantable cardioverter defibrillator (ICD), the AnalyST™ Accel ICD and the Promote™ Accel cardiac resynchronization therapy defibrillator (CRT-D); the Durata™ high-voltage cardiac lead; and its SJM Confirm™ implantable cardiac monitor.

“These devices demonstrate St. Jude Medical’s commitment to providing physicians access to timely, actionable information about their patients’ heart rhythms, and unique tools that allow them to treat individual patient needs,” said Eric S. Fain, M.D., president of the Cardiac Rhythm Management Division at St. Jude Medical. “The approval of these new products gives physicians the ability to improve cardiac disease management.”